Our team has a wealth of experience and expertise in the development of protein/peptide therapeutics and an in-depth understanding of the needs of the pharmaceutical industry when it comes to the development and manufacture of novel, effective and safe biologics. In addition, with our business acumen and experience of forming strategic alliances we are working to build effective partnerships to deliver biologics solutions:
Dr David Simpson | CEO
After 15 years’ in biologics development and commercialization with Cobra Biologics, Eden Biodesign and Actavis, Dave supported IP Group from October 2011 to develop Glythera's business strategy and fundraising activities. Having co-founded Glythera as Chief Operating officer in March 2012, Dave was appointed CEO in February 2014 and continues to lead the strategic direction and growth of the business.